| 000 | 02564cam a2200193 4500 | ||
|---|---|---|---|
| 001 | NMDX7810 | ||
| 008 | 120401t2017 xxu||||| |||| 00| 0 eng d | ||
| 100 | _aMoghul, M. | ||
| 240 | _aJournal of Endourology | ||
| 245 | _aGallium labelled-prostate-specific membrane antigen-positron emission tomography/computed tomography (GA-PSMA-PET/CT) vs. choline-PET/CT in malignant prostate cancer: a systematic review | ||
| 260 | _c2017 | ||
| 500 | _aNMUH Staff Publications | ||
| 500 | _aEMBASE | ||
| 500 | _a31 | ||
| 520 | _a<span style="font-size: 10pt;"><span style="color: #4a4a4a; font-family: Lato, &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; text-decoration-color: initial;">Introduction&amp;Objective: Recently the role of Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) has become more prominent in helping to diagnose recurrent prostate cancer and malignant prostate cancer. The role of PSMA as a radiotracer appears to be surpassing that of choline tracers in prominent centres. We have evaluated current data regarding the use of PSMA-PET/CT scans compared to Choline PET/CT scans. Materials and Methods: We performed a review of PubMed/Medline, Clinical trials.gov and the Cochrane Library in March 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Results: 4 studies were included in this review having directly compared 68GA-PSMA-PET/CT and Choline PET/CT scans. Choline tracers used were 11C in one study and 18F in the other studies. Overall 230 men had both 68GA-PSMA PET and choline-PET/CT scans. Overall detection rates for biochemical recurrence were 81.1% for GA-PSMA-PET and 70.3% for choline-PET/CT. This indicates that GA-PSMA PET/CT is significantly better than choline-PET/CT for detecting recurrence of prostate cancer (P &lt; 0.005). 68GA-PSMA-PET/CT also showed higher detection rates at lower PSA values. Lesions missed on PSMAPET/CT but captured by choline-PET/CT were found to be negligible (1-2%). Conclusions: 68GA-PSMA-PET/CT appears to offer better diagnostic capability than choline-PET/CT, as well as similar if not higher sensitivities and specificities, indicating justification for replacing choline as the radiotracer of choice in prostate cancer and guiding further management decisions.</span>&nbsp;[Conference abstract]</span> | ||
| 700 | _aRhudd, A. | ||
| 700 | _aRai, B. | ||
| 856 | _uhttps://www.liebertpub.com/doi/pdf/10.1089/end.2017.29029.abstracts | ||
| 999 |
_c76589 _d76589 |
||